University of California at San Diego, San Diego, California, USA.
Pediatrics. 2012 Mar;129(3):480-4. doi: 10.1542/peds.2011-2121. Epub 2012 Feb 27.
The Surfactant Positive Airway Pressure and Pulse Oximetry Randomized Trial (SUPPORT) antenatal consent study demonstrated that mothers of infants enrolled in the SUPPORT trial had significantly different demographics and exposure to antenatal steroids compared with mothers of eligible, but not enrolled infants. The objective of this analysis was to compare the outcomes of bronchopulmonary dysplasia, severe retinopathy of prematurity, severe intraventricular hemorrhage or periventricular leukomalacia (IVH/PVL), death, and death/severe IVH/PVL for infants enrolled in SUPPORT in comparison with eligible, but not enrolled infants.
Perinatal characteristics and neonatal outcomes were compared for enrolled and eligible but not enrolled infants in bivariate analyses. Models were created to test the effect of enrollment in SUPPORT on outcomes, controlling for perinatal characteristics.
There were 1316 infants enrolled in SUPPORT; 3053 infants were eligible, but not enrolled. In unadjusted analyses, enrolled infants had significantly lower rates of death before discharge, severe IVH/PVL, death/severe IVH/PVL (all < 0.001), and bronchopulmonary dysplasia (P = .003) in comparison with eligible, but not enrolled infants. The rate of severe retinopathy of prematurity was not significantly different. After adjustment for perinatal factors, enrollment in the trial was not a significant predictor of any of the tested clinical outcomes.
The results of this analysis demonstrate significant outcome differences between enrolled and eligible but not enrolled infants in a trial using antenatal consent, which were likely due to enrollment bias resulting from the antenatal consent process. Additional research and regulatory review need to be conducted to ensure that large moderate-risk trials that require antenatal consent can be conducted in such a way as to ensure the generalizability of results.
表面活性物质正压通气和脉搏血氧饱和度随机试验(SUPPORT)的产前知情同意研究表明,与有资格但未入组的婴儿的母亲相比,入组 SUPPORT 试验的婴儿的母亲在人口统计学特征和产前皮质类固醇暴露方面存在显著差异。本分析的目的是比较支气管肺发育不良、严重早产儿视网膜病变、严重脑室出血或脑室周围白质软化(IVH/PVL)、死亡以及死亡/严重 IVH/PVL 的发生率,以评估入组 SUPPORT 的婴儿与有资格但未入组的婴儿。
在单变量分析中比较了入组和有资格但未入组婴儿的围产期特征和新生儿结局。创建模型以测试入组 SUPPORT 对结局的影响,同时控制围产期特征。
共有 1316 名婴儿入组 SUPPORT;3053 名婴儿有资格但未入组。在未调整的分析中,与有资格但未入组的婴儿相比,入组婴儿的出院前死亡率、严重 IVH/PVL、死亡/严重 IVH/PVL(均<0.001)和支气管肺发育不良(P=0.003)的发生率显著降低。严重早产儿视网膜病变的发生率无显著差异。调整围产期因素后,试验入组不是任何测试临床结局的显著预测因素。
这项分析的结果表明,在使用产前知情同意的试验中,入组和有资格但未入组的婴儿之间存在显著的结局差异,这可能是由于产前知情同意过程中的入组偏倚所致。需要进行更多的研究和监管审查,以确保需要产前知情同意的大型中危风险试验能够以确保结果可推广性的方式进行。